<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206568</url>
  </required_header>
  <id_info>
    <org_study_id>PER511</org_study_id>
    <nct_id>NCT02206568</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomised Trial Investigating Pharmacokinetic Properties of Ultra-Rapid-Acting Insulin Lispro (URAL) in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perosphere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut f√ºr Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Perosphere, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the total pharmacodynamic response of URAL and insulin lispro.

      To compare the total pharmacokinetic exposure between URAL and insulin lispro.

      To assess the safety and tolerability of URAL and insulin lispro.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of URAL</measure>
    <time_frame>1 day</time_frame>
    <description>Area under the serum insulin lispro concentration-time curve from 0-30 minutes after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of appearance of serum insulin lispro</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of time to reach insulin lispro concentration &gt;30 pmol/L in the serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 day</time_frame>
    <description>Assessment of safety and tolerability of URAL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>URAL vs. Insulin lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URAL</intervention_name>
    <arm_group_label>URAL vs. Insulin lispro</arm_group_label>
    <other_name>Ultra-Rapid-Acting Insulin Lispro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Male subects age 18-65 years inclusive

          3. Type 1 diabetes mellitus diagnosed clinically &gt;= 12 months

          4. Treatment with multiple daily insulin injections or CSII &gt;= 12 months

          5. Current total daily insulin treatment &lt;1.2 (I)U/kg/day

          6. Current total daily bolus insulin treatment &lt;0.7 (I)U/kg/day

          7. Body mass index 18.0-30.0 kg/m2 inclusive

          8. HbA1c =&lt;9.0% by local laboratory analysis (one retest within a week is permitted with
             the result of the last test being conclusive)

          9. C-peptide =&lt; 0.30 nmol/L

        Exclusion Criteria:

          1. Known or suspected hypersensitivity to trial products or related products

          2. Previous participation in this trial. .

          3. Receipt of any non-marketed investigational product within 3 months

          4. Clinically significant abnormal haematology, biochemistry, liver enzymes, or
             coagulation screening tests

          5. Suffer from or history of a life threatening disease or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,
             endocrinological, haematological, dermatological, venereal , neurological, psychiatric
             diseases or other major disorders

          6. History of deep leg vein thrombosis or a frequent appearance of deep leg
             veinthrombosis in 1st degree relatives

          7. Cardiac problems defined as decompensated heart failure (New York Heart Association
             class III and IV) at any time and/or angina pectoris within the last 12 months and/or
             acute myocardial infarction at any time.

          8. Supine blood pressure at screening outside the range of 90-140 mmHg for systollic or
             50-90 mmHg for diastolic . Pulse outside 50 to 90 bpm.

          9. Clinically significant abnormal ECG at screening.

         10. Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular
             autonomic neuropathy.

         11. Any disease or condition that, inthe opinion of the Investigator, would represent an
             unacceptable risk for the subject's safety.

         12. Subject positive for HBs-Ag, HCV-Ab

         13. Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies, or HIV-1
             antigen according to locally used diagnostic testing.

         14. History of multiple and/or severe allergies to drugs or foods or a history of severe
             anaphylactic reaction.

         15. Subject who has donated blood or plasma in the past month or more than 500 mL within 3
             months.

         16. Surgery or trauma with significant blood loss (more than 500 mL) within 3 months.

         17. Current treatment with systemic (oral, IV, or inhaled) corticosteroids, monoamine
             oxidase inhibitors, NSAID, prostaglandin blockers, systemic non-selective
             beta-blockers, growth hormone (last 3 months), non-routine vitamins or herbal products
             (last 2 weeks). Yhyroid hormons are not allowed unless the use of these has been
             stable during the last 3 months. Routine vitamins are permitted up to 48 hours prior
             to dosing.

         18. Significant history of alcoholism and/or drug/chemical abuse as per Investigator's
             judgement or a positive result in the urine drug/alcohol breath test screen at the
             screening visit.

         19. Heavy smoker

         20. Not able or willing to refrain from smoking and use of nicotine.

         21. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemia event during the last
             12 months) or hypoglycaemic unawareness.

         22. Subject with mental incapacity or language barriers precluding adequate understanding.

         23. Potentially non-compliant or uncooperative during the trial.

         24. Any condition that would interfere with trial participation or evaluation of results.

         25. No relevant lipodystrophy within the area of drug administration and Doppler
             sonography.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alin Stirban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut fur Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut fur Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>phase 1</keyword>
  <keyword>insulin lispro</keyword>
  <keyword>male subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

